Aimmune Therapeutics Stock News

Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2020 contest. Matt McCall's pick for the contest is Aimmune Therapeutics (NASDAQ:AIMT).Six months ago, I introduced you to Ai

Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters revi

From Parkinson's to peanut allergy, pandemic puts brakes on new drugs

DBV Technologies still expects to receive an FDA decision in early August for its peanut allergy patch. But on Friday the company, which is headquartered

The company provided a grim business update.

JPMorgan Chase & Co. lowered its holdings in Aimmune Therapeutics Inc (NASDAQ:AIMT) by 13.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission

Aimmune Therapeutics Inc (NASDAQ:AIMT) has been given an average recommendation of “Hold” by the fourteen ratings firms that are currently covering the company, MarketBeat.com reports. One equitie

In this article you are going to find out whether hedge funds think Aimmune Therapeutics Inc (NASDAQ:AIMT) is a good investment right now. We like to check what the smart money thinks first before doi

Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?

Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Tuesday, BidAskClub reports. AIMT has

Swiss National Bank increased its position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 2.5% during the first quarter, according to the company in its most recent disclosure with the Securit

Palforzia, approved in late January and priced at $890 per month, is designed to reduce sensitivity to peanuts by exposing patients to refined version of peanut flour over time. Palforzia received ap

New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy

Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented